Recently, a consensus statement on the use of TPO-RAs in adult patients affected by ITP identified patient characteristics that may be potential indicators of remission or relapse during tapering or discontinuation of TPO-RAs. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.